---
title: Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
nct_id: NCT03850379
overall_status: COMPLETED
phase: PHASE2
sponsor: Henry Ford Health System
study_type: INTERVENTIONAL
primary_condition: Prophylaxis
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03850379.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03850379"
ct_last_update_post_date: 2025-10-20
last_seen_at: "2026-05-12T06:13:08.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant

**Official Title:** Ciprofloxacin Versus Levofloxacin and Rate of Breakthrough Infections in Hematopoietic Stem Cell Transplant Patients

**NCT ID:** [NCT03850379](https://clinicaltrials.gov/study/NCT03850379)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 308
- **Lead Sponsor:** Henry Ford Health System
- **Conditions:** Prophylaxis, Stem Cell Transplant Complications
- **Start Date:** 2018-03-14
- **Completion Date:** 2024-08-30
- **CT.gov Last Update:** 2025-10-20

## Brief Summary

Ciprofloxacin and levofloxacin are both in guidelines to use for prophylaxis in autologous and allogeneic Stem cell transplant.Ciprofloxacin was recently replaced by levofloxacin as the preferred agent in some transplant centers. In some small retrospective studies ciprofloxacin prophylaxis was associated with a higher rate of breakthrough gram positive bloodstream infections. However, the optimum oral agent for antibacterial prophylaxis in transplant recipients remains uncertain.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients 18-75 years of age with a diagnosis of a hematological malignancy. Meet the stem cell transplant program criteria to undergo autologous or allogeneic hematopoietic stem cell transplantation.

Exclusion Criteria:

* Prolonged QT
* Allergies to ciprofloxacin or levofloxacin
```

## Arms

- **Levo** (EXPERIMENTAL) — Levofloxacin 500 mg once daily
- **Cipro** (ACTIVE_COMPARATOR) — Ciprofloxacin 500 mg BID

## Interventions

- **Levofloxacin** (DRUG) — This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000
- **Ciprofloxacin** (DRUG) — This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000

## Primary Outcomes

- **Proportion of Bloodstream Bacterial Infections** _(time frame: 60 days post stem cell transplant)_ — to assess proportion of bloodstream bacterial infections in the ciprofloxacin group compared to levofloxacin group up to day 60 after stem cell transplant

## Locations (1)

- Henry Ford, Detroit, Michigan, United States

## Recent Field Changes (last 30 days)

- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.henry ford|detroit|michigan|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03850379.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03850379*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*